Command Palette

Search for a command to run...

shukra-pharmaceuticals

34.41+1.99%
Market Cap
₹0.00 Cr
Stock P/E
0.00
ROCE
0.00%
ROE
0.00%
Book Value
₹0.00

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings
Distribution
Promoter
Public
Others

From Last Concall

No Concall Summary

Conference call summary is not available for this stock.

Peers Summary

Growth Outperformer

Shukra Pharmaceuticals Ltd. lags significantly behind its peers in growth and profitability metrics, making it a high-risk investment. Meanwhile, companies like Sun Pharmaceutical Industries Ltd. and Dr. Reddy's Laboratories Ltd. show strong performance in profitability and growth, indicating their market leadership and better investment potential.

Key Points
  • Shukra Pharmaceuticals has no revenue or earnings growth, indicating financial stagnation.
  • Sun Pharmaceutical and Dr. Reddy's lead in profitability metrics, particularly ROE and EPS.
  • Cipla Ltd. and Divi's Laboratories offer good valuation metrics compared to their earnings and growth.
  • Mankind Pharma shows impressive growth but has a relatively high PE ratio.
Top Performers
Sun Pharmaceutical Industries Ltd.

Strong revenue and EPS growth (YoY: 8.42%, EPS: 45.55), high ROE (16.13%), indicating solid profitability.

Dr. Reddy's Laboratories Ltd.

High profitability with ROE of 21.76%, strong EPS growth (YoY: 16.54%, EPS: 68.07), and low valuation ratios.

Cipla Ltd.

Excellent valuation metrics (PE: 23.73, PEG: 0.35) combined with strong growth (YoY: 13.28%), making it a value pick.

Leveling the playing field in markets.

© 2025 EQHQ Technologies Pvt Ltd

"Information provided is for educational purposes only and not financial advice.